Vertex Has Cured 69 Sickle Cell Patients in 30 Months. There Are 100,000 Left.
The FDA just expanded the world's first CRISPR gene therapy to children as young as two. At 64 patients per year, treating every eligible American would take 336 years.
Sixty-nine. That is the total number of human beings who have received Casgevy, the world's first CRISPR-based gene therapy, since its initial FDA approval in December 2023, a number so small it would fit in a single hospital ward. Five were treated in 2024, and sixty-four in 2025. Sickle cell disease affects approximately 100,000 people in the United States, more than 90% of them Black. On July 1, 2026, the FDA expanded Casgevy's label to children as young as two years old, adding roughly 5,500 newly eligible patients to the approximately 16,000 who were already cleared for treatment. Scientifically, the expansion is remarkable: 100% of evaluable pediatric patients in the clinical trial remained free of severe pain crises for over a year. Manufacturing and distribution math behind it is less inspiring, and it raises a question that nobody in the gene therapy space seems willing to answer directly.
At the 2025 treatment rate of 64 patients per year, reaching every eligible American with sickle cell disease would require 336 years.
What Casgevy Does, and What It Costs
Casgevy works by harvesting a patient's own blood stem cells, editing them with CRISPR/Cas9 to reactivate fetal hemoglobin production (which suppresses sickling), and infusing the modified cells back into the patient after myeloablative conditioning, a chemotherapy regimen that destroys the existing bone marrow to make room for the edited cells. Clinical results are extraordinary: in the pediatric trial published June 29 in the New England Journal of Medicine, all eight evaluable children with sickle cell disease remained free of severe vaso-occlusive crises for at least 12 consecutive months. Eight of nine children with transfusion-dependent beta thalassemia achieved transfusion independence, with a median duration of 20.1 months. FDA officials granted approval in 53 days, its fastest-ever action for a gene therapy, under the Commissioner's National Priority Voucher pilot program.
At $2.2 million per patient, the list price, making it one of the most expensive single-administration therapies ever approved, though its only competitor, Genetix Biotherapeutics' Lyfgenia (formerly bluebird bio), costs $3.1 million and carries a black box warning for myelodysplastic syndrome risk. By the end of 2025, about 90% of US patients had reimbursed access to Casgevy, according to Vertex. Insurance is not the bottleneck; manufacturing is.
The Throughput Problem
Each Casgevy treatment is a bespoke, months-long medical procedure. Stem cells must be collected from the individual patient via apheresis, shipped to a manufacturing facility where they are gene-edited and expanded over weeks, quality-tested against specifications that cannot be relaxed without regulatory consequence, and shipped back to the treatment center in a cold chain that tolerates zero error. Meanwhile, the patient undergoes fertility preservation counseling, then myeloablative conditioning that requires extended hospitalization and carries significant infection risk, and then waits. Engraftment takes weeks, and recovery takes months, and the entire patient journey from referral to infusion spans four to six months for a single person.
Vertex currently operates between 40 and 50 authorized treatment centers in the United States, with a global target of 75, and in 2025 those centers collectively treated 64 patients. Do the division. That is 1.3 patients per center per year, generating roughly $2.8 million in Casgevy revenue per center annually for one of the most complex procedures in modern medicine.
After expansion, the eligible population in the United States is approximately 21,500 patients with sickle cell disease who have recurrent vaso-occlusive crises (16,000 aged 12 and older, plus ~5,500 children aged 2-11). Adding transfusion-dependent beta thalassemia patients brings the total closer to 22,500. The throughput math at various scaling assumptions:
| Treatment Rate | Patients/Year | Years to Reach 21,500 Eligible US SCD Patients |
|---|---|---|
| 2025 actual | 64 | 336 |
| Vertex funnel (initiated) | ~300 | 72 |
| 5× current | 320 | 67 |
| 10× current | 640 | 34 |
| 50× current | 3,200 | 6.7 |
Vertex's Q4 2025 earnings call disclosed that approximately 300 patients had initiated the treatment journey and about 150 had completed first cell collections. If every one of those 300 proceeds to infusion, the company still treats less than 1.4% of the eligible US population per year. A 50-fold increase in throughput, which would require approximately 2,500 authorized treatment centers running at current per-center capacity (or a dramatic increase in per-center volume), brings the timeline down to under seven years. No one is projecting that kind of infrastructure buildout, and the absence of that projection tells you everything.
The Revenue Paradox
The total addressable market for Casgevy in the United States alone is $47.3 billion: 21,500 eligible SCD patients multiplied by $2.2 million each. Vertex's full-year 2025 Casgevy revenue was $115.8 million, or 0.24% of the domestic TAM. Vertex guides to $500 million or more in combined 2026 revenue from Casgevy and Journavx (its non-opioid painkiller). If Casgevy captures $300 million of that, the therapy would still have exhausted only 0.63% of its US addressable market after three full years of commercial availability.
At the 2025 revenue pace of $115.8 million per year, exhausting the $47.3 billion US TAM would take 408 years. This is not a demand problem, and it is not an insurance problem. It is a fundamental constraint of personalized cell therapy: you cannot scale an autologous treatment the way you scale a pill.
The Age Inversion
The FDA's age expansion introduces a counterintuitive economic dynamic. Lifetime sickle cell disease management costs in the United States run between $25,000 and $35,000 annually, depending on severity and complications. For a two-year-old with approximately 70 years of disease burden ahead, that totals $1.75 million to $2.45 million in discounted lifetime healthcare spending. At $2.2 million, Casgevy is roughly cost-neutral for the youngest patients. For toddlers, the math works.
For a 30-year-old with 40 years remaining, the same calculation yields $1.0 million to $1.4 million in lifetime management costs, which means the cure, at $2.2 million, becomes cost-ineffective by a factor of nearly two. Health economics researchers have estimated Casgevy's cost-effectiveness threshold between $1.35 million and $2.05 million, assuming a societal willingness to pay of $100,000 to $150,000 per quality-adjusted life year. The math is stark. The therapy's $2.2 million price exceeds the upper bound of its own cost-effectiveness range for most adult patients.
This creates a genuine paradox: the age expansion to two-year-olds is justified precisely because younger patients have longer benefit horizons and face the greatest cumulative organ damage. The clinical evidence supports early treatment, but the patients with the most accumulated disease burden, adults who have suffered decades of pain crises and irreversible organ damage, are the ones for whom the economic case is weakest. The science and the economics both say treat early, and the throughput says we can treat barely anyone at all.
The Strongest Case for Casgevy
The strongest counterargument to this throughput critique is that Casgevy is not trying to treat everyone right now; it is building the infrastructure for personalized medicine. Early curative interventions in children prevent irreversible organ damage, strokes, and the accumulated disability that drives the most expensive adult SCD care. A two-year-old cured today avoids decades of emergency hospitalizations, chronic transfusions, and opioid dependency. Even if only 300 children receive treatment per year initially, those 300 represent lives fundamentally altered in a way that hydroxyurea and pain management never achieve.
Bone marrow transplant precedent supports this view. When allogeneic transplant was first approved for SCD, throughput was equally limited, constrained by matched donors, treatment center capacity, and conditioning toxicity. Over 30 years, transplant volume grew as expertise diffused and conditioning regimens improved. Casgevy has an advantage transplant never had: no donor matching required. Every patient is their own donor. That eliminates the most intractable bottleneck in traditional transplant and provides a structural basis for faster scaling.
Additionally, 90% of US patients now have insurance coverage for the therapy. Vertex reports robust referral pipelines, meaning the demand signal is genuine and the waiting rooms are full. What remains is execution, and execution at this scale means solving a logistics problem that no pharmaceutical company has ever solved: how to manufacture a bespoke, patient-specific biological product at the speed and volume of mass-market medicine.
The Equity Problem Nobody Is Discussing
More than 90% of Americans with sickle cell disease are Black, and the treatment requires months of intensive medical engagement: referral to a specialized center (often hundreds of miles from the patient's home), fertility counseling and preservation for patients who may want children someday, apheresis to harvest stem cells, weeks of hospitalization for the myeloablative conditioning and engraftment, and months of recovery during which the patient cannot work, cannot care for their family, and cannot earn a living. Authorized treatment centers are clustered in major metropolitan academic medical centers. Median Black household income in the United States is approximately $52,860, versus $80,610 for all households. Even with full insurance coverage, the indirect costs of treatment, lost wages, childcare, travel to a distant treatment center, and months of recovery, fall disproportionately on the population this therapy was designed to serve.
No one in the CRISPR gene therapy space is publicly addressing this structural access gap with specific solutions, because Vertex's investor communications focus on treatment center activation counts and patient funnel metrics rather than the demographic breakdown of the 69 patients treated to date, the geographic distribution of referrals, or the dropout rate between referral and infusion.
Limitations
This analysis relies on publicly available financial disclosures and regulatory documents. Vertex does not publish patient-level demographic data, per-center treatment volumes, or detailed manufacturing throughput metrics. The 21,500 eligible patient estimate combines Vertex's stated figures for adults (16,000) and the newly eligible pediatric population (~5,500), but the true number of patients who would both qualify medically and elect to undergo the procedure is likely smaller. Lifetime SCD cost estimates vary significantly across studies, and the $25,000-$35,000 annual figure used here represents a mid-range estimate that may not reflect the full spectrum of disease severity. The throughput projections assume a static eligible population; in practice, approximately 1,900 babies are born with SCD in the US annually, continuously adding to the treatment-eligible pool.
What This Means for You
If you are a parent of a child with sickle cell disease: Casgevy is now approved for children as young as two, and the clinical data shows 100% of evaluable pediatric patients remained free of severe pain crises for at least 12 months. Ask your hematologist about referral to an authorized treatment center. Approximately 90% of US patients have reimbursed access. Earlier treatment prevents more cumulative organ damage. Do not wait for the "next generation" of the therapy; the current version works.
If you are evaluating SCD therapies as a payer or hospital administrator: the throughput constraint is real, and it shapes the revenue trajectory. Casgevy will not scale like a small-molecule drug. Budget for 1-2 patients per authorized center per year in the near term, with incremental growth as manufacturing capacity expands. Cost-effectiveness math favors pediatric patients strongly, which means younger patients should be prioritized in treatment sequencing if center capacity is the binding constraint.
If you are an investor in Vertex (VRTX): the $47.3 billion US TAM sounds enormous, but at current throughput, revenue realization is measured in decades. The company's non-CF guidance of $500M+ for 2026 mixes Casgevy with Journavx, making it difficult to isolate gene therapy momentum. Watch Q2 and Q3 2026 treatment volumes closely. One number matters more than the revenue figure: patients infused per quarter. If that number does not reach triple digits by year-end, the 336-year throughput math applies for longer than anyone's valuation model assumes.
The Bottom Line
CRISPR gene editing can cure sickle cell disease, and we have known this since December 2023, and the pediatric data published last week makes the case even more compelling than it was when the Nobel committee honored Jennifer Doudna and Emmanuelle Charpentier six years ago. The biology is solved. Extending the approval to two-year-olds is the correct clinical decision, backed by 100% efficacy in evaluable patients and sound medical logic about early intervention preventing the cascade of organ damage, stroke, chronic pain, and premature death that defines untreated sickle cell disease from childhood through middle age. What is not solved is the gap between what medicine can do for one person and what the healthcare system can deliver to 100,000. Sixty-nine patients in 30 months. Approximately 1,900 new SCD births per year, each one adding another name to a waiting list that does not officially exist but functionally grows longer every quarter. The cure exists. Its conveyor belt that delivers it runs at a speed that would be recognizable to a 19th-century hospital, and no amount of investor enthusiasm about CRISPR's transformative potential changes the fact that manufacturing miracles one patient at a time is not a scalable business model.